-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, the company and its subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd., Shandong Shengdi Pharmaceutical Co., Ltd., and Chengdu Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue “Drug Clinical Trial Approval Notice” for HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets, which will conduct clinical trials in the near future.

Zhitongcaijing·12/19/2025 12:09:16
Listen to the news
Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, the company and its subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd., Shandong Shengdi Pharmaceutical Co., Ltd., and Chengdu Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue “Drug Clinical Trial Approval Notice” for HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets, which will conduct clinical trials in the near future.